title: PET/CT, MR, and PET/MR in Lymphoma and Melanoma.
abstract: With the introduction of hybrid imaging technologies such as PET/CT and recently PET/MRI, staging and therapy-response monitoring have evolved. PET/CT has been shown to be of value for routine staging of FDG-avid lymphomas before as well as at the end of treatment. For interim staging, trials are ongoing to evaluate the use of PET/CT. In melanoma, PET/CT can be recommended for stages III and IV diseases for initial staging and before surgery. Studies investigating the use of PET/CT for early therapy response are promising. The role of PET/MR in lymphoma and melanoma imaging has to be defined because no larger studies exist so far. There may be an application of PET/MR in research especially for tumor characterization and therapy response. Furthermore, the potential role of non-FDG tracers is elucidated regarding the assessment of treatment response in targeted drug regimens.
authors.affiliation: Department of Radiology, Diagnostic and Interventional Radiology, Eberhard Karls University Tübingen, Tübingen, Germany. Electronic address: nina.schwenzer@med.uni-tuebingen.de.
authors.forename: Nina F
authors.initials: NF
authors.lastname: Schwenzer
authors.affiliation: Department of Radiology, Diagnostic and Interventional Radiology, Eberhard Karls University Tübingen, Tübingen, Germany.
authors.forename: Anna Christina
authors.initials: AC
authors.lastname: Pfannenberg
mesh_terms: D000818:Animals; D006801:Humans; D008223:Lymphoma / Q000175:diagnosis* / Q000473:pathology / Q000601:surgery / Q000628:therapy; D008279:Magnetic Resonance Imaging / Q000379:methods*; D008545:Melanoma / Q000175:diagnosis* / Q000473:pathology / Q000601:surgery / Q000628:therapy; D064847:Multimodal Imaging / Q000379:methods*; D049268:Positron-Emission Tomography / Q000379:methods*; D014057:Tomography, X-Ray Computed / Q000379:methods*